Get started

PHARMA

Nasdaq Healthcare: Closing on January 15thIf you like this idea, don't forget to support it clicking the Like Button! Positive session for Nasdaq Healthcare that gained 0.39%. However, I still see the possibility of a retracement over the basis of the Bollinger Bands indicator (orange crosses). I was waiting with anxiety today's session to check for a signal of retracement, and it comes with the third candles (17:00 - 19:00) The situation is also confirmed by RSI and CCI indicators. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:IXHCLong
by Investing_Fellow
Healthcare: Closing on January 14thGood session for the Nasdaq Healthcare Index, that closed the day with a 1.30% gain. Bullish sentiment is still driving trades. However next session could be characterized by a retracement around the basis of the Bollinger Bands indicator (orange crosses). This is a daily analysis. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:IXHCLong
by Investing_Fellow
GWPH is a clear buyWow, great trend, much support. Hey, I've said it before I'll say it again, I'm no technical analysis guru. I think most of it is hooplah. Have you ever heard of the guys on Wall Street who threw darts at random stocks on a wall and those picks ended up performing better than most professional hedge fund managers? Yeahhh, exactly. I personally don't believe in most of these unicorn indicators. Goku flying on a Ichimoku cloud over here, fucking RSI up your ass over there. I don't look at any of it. (bUt YoU hAVe tHe RsI uP rIGhT nOw) shhhhhhh it's for giggles. Now let me tell you what I do do (heh heh). I follow a rule I've established with myself before I go in and buy/sell a stock. I only commit to that action of exchanging the stock for cash or vice versa unless my conditions are met. Want to know what those conditions are? PSSHHHH. I'm not telling. Not that you care anyway. I'm not like, the best trader in the world. But I heavily believe part of trading is understanding the psychology of the market and beating the other guy - except for whale behavior but you can argue there's a psychological aspect to that as well (detecting that shit is hard tho) - so telling you my strategy is a joke and that's why I rarely believe in anyone who tells me there's. Anyyyyywho. What I will reveal is my bullishness on GW Pharmaceuticals. I'll even reveal what prices I bought in at - an average cost of $103.13 and I will be buying more good sir. I took a look at this companies balance sheet compared to last year and I swear I got half a chub. For one, GWPH's product Epidolex has competitor advantage being the only FDA approved cannabidiol product to treat two forms of epilepsy in children. Over 18,000 children suffer from LGS and Dravet Syndrome in America (the forms of epilepsy the prescription treats). As of now 7,600 patients have received Epidolex for treatment resulting in $31 million in sales for this product. Future sales can potentially double just for America alone. The company is gearing up in the EU market as well. Not to mention they are testing the same prescription in treating a disease that affects 1-2 million people worldwide. This baby is going to the moon given FDA approval for the treatment. But of course that's an "if". Considering the hard facts I like that the companies' assets are outpacing its liabilities and looking at last years' balance sheet compared to this years' this stock was either grossly over valued last year and slightly under valued this year or damn near bubble euphoria territory last year and fairly priced this year. There could be a third scenario that this stock price is still overvalued but man does this companies growth story look attractive. I'm buying!! P.S - I am a random dude who doesn't know shit about shit. I'm just reading books, reading balance sheets, watching YouTube videos trying to figure out how to value businesses. I got involved in the stock market 3 years ago and I'm just straight up passionate about it dawg. Think it was my real calling truth be told. I'm documenting for future purposes. Follow my trades if you want, just don't cry if you randomly read this and got convinced to buy something because of a stranger. I learned the hard way to never do that again. I only read other peoples recommendations of stocks to get an understanding of how other peeps are valuating companies. I don't even read that trade junk anymore, I've already got my set of rules. And I also only execute very few trades because as we know most traders do not beat the market. If you think you can I encourage you to try to get into an Ivy league cuz you're chances are roughly the same. Good luck out there folks. Holla atcha boy
GLong
by misckid
$TTNP - Set up for a Growth Stock in 2020 5 X + CandidateI will update this article I just wanted to get the idea down because this is capable of 2-4 x in short amount of time.. So rough notes but wanted to have it documented real time Analyst have maintained a .75 and 1 target here which is at the very least 3-4 x from current prices. $TTNP - Going to be a 5-10 X candidate 2020 For a swing trade . 2020 will be the first year company will become a growth stock Major analyst have a 1 target on this as unlikely FINRA will allow for another RS so soon. So they have 1 option get the stock over 1... Remember even company has the option doesn't mean FINRA will approve. Analyst have also maintained a .75 and 1 target here which is at the very least 3-4 x from current prices. The last Bio tech i posted on went 10x in a short amount of time and $TTNP has tremendous upside going forward as much of bad news is behind them. They laid down the infastructure for growth in 2019 so 2020 should be a growth year. Sadly, the Opioid crisis isnt going away. $TTNP is positioned to help the fight against the epidemic and should also profit with that endeavor. $TTNP has 5-10x + potential chart has lots of gaps up Do your DD , recent board appointment and all the ground work laid in 2019 for it to become a growth stock in 2020. My thoughts .. TTNP is at .20 now
NASDAQ:TTNPLong
by InvisbleHand
6
Alexion: Today's opening is confirming the bullish assumptionGood spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud). I was waiting for today's opening to confirm a bullish position. Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
ALong
by Investing_Fellow
Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic. The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline. Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:BIIBLong
by Investing_Fellow
VSTM - Bear Trend ReversalBear Trend Reversal - Long term downtrend rejected with bullish RSI divergence on the weekly. These hops off a long-term bear trend reversals can be swift and powerful. I've played these before and won (DAN...TQQQ after '18 Christmas)..but I've also played these and lost (MAXR). I've previously played these directly on the instrument, but this time I'm playing this with 10 buys of $2 March 20, 2020 calls. Hoping to see a continued surge of implied volatility for these options as I don't plan on holding them through expiry. That being said, I've yet to really win on any of my options trades...but IV is on the up and up since my purchase so we'll just have to wait'n'see.
NASDAQ:VSTMLong
by Ascott156
1
Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L) Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide. Market Cap: £4.79Billion The long-term trend on Hikma remains bullish. The corrective move lower in recent weeks has found some support at the 38.2% Fibonacci level. The posting of a bullish engulfing candle while simultaneously breaking from a wedge pattern is bullish for short term sentiment. Further upside is expected from here, targeting the previous highs at 2345p from 15th March 2017. Stop: 1920p Target 1: 2210p Target 2: 2345p Target 3: 2400p Interested in UK Stocks? Join our free Telegram channel for up to date analysis on the best main market opportunities in the UK right now - t.me
LSE:HIKLong
by Investamate
ALKS BUY 03.09.2019BUY signal at 20.98 $ Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. If you want to see more history of this strategy, I will able to show you if you request me. ATTENTION this strategy may has downtrend about 20%, so you can split your buy order, that you have not big downtrend. __________________________________________________________________________ You can use the signals independently or like indicator of trends together with other indicators in your trading strategy. Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies. You use these signals inside your strategies at your own risk. The chart shows the last trades on the product + the last signal. I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile. Therefore, subscribe and watch for that profile. The signals rare but useful.
NASDAQ:ALKSLong
by price_and_time
$AMPE Ampio Pharmaceuticals Inc A Good Risk/Reward PlayWe are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on. Currently trading at $.62 a share, the 52-week low is $.35 a share. We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's what the company said last month in its update: Ampio Pharmaceuticals has been in contact with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) following its re-submission of a revised protocol for AP-013, which the Company believes implements all of the Agency's recommendations provided since the beginning of the SPA review cycle. The Agency confirmed that it would make every effort to expedite this review, however due to a heavy workload, they were not able to commit to providing a response to the Company's SPA re-submission earlier than the 45-day window outlined in the Guidance for Industry Special Protocol Assessment, leading the Company to expect the response will be in mid-June rather than late May 2019, as previously predicted. There is some debate on social channels as to when this news will hit the tape. Some are saying any day now, while others are saying after the July 4th holiday. As always, trade with caution and use protective stops. Good luck to all!
ALong
by OptionsGains